XML 45 R16.htm IDEA: XBRL DOCUMENT v3.20.1
Note 1 - Significant Accounting Policies (Tables)
 3 Months Ended
Mar. 31, 2020
Notes Tables  
Debt Securities, Available-for-sale [Table Text Block]
    March 31, 2020
    Amortized
Cost		   Accrued
Interest		   Gross
Unrealized
Gains		   Gross
Unrealized
Losses		   Estimated
Fair Value
Obligations of the U.S. Government and its agencies   $
4,501
     $
44
     $
8
     $
-
     $
4,553
  
Corporate debt securities    
5,387
      
52
      
2
      
(1
 )    
5,440
  
Certificates of deposit    
1,180
      
7
      
5
      
-
      
1,192
  
Total investments   $
11,068
     $
103
     $
15
     $
(1
 )   $
11,185
  
    December 31, 2019
    Amortized
Cost		   Accrued
Interest		   Gross
Unrealized
Gains		   Gross
Unrealized
Losses		   Estimated
Fair Value
Obligations of U.S. Government and its agencies   $
10,488
     $
50
     $
23
     $
-
     $
10,561
  
Corporate debt securities    
9,742
      
59
      
10
      
(1
 )    
9,810
  
Certificates of deposit    
1,669
      
7
      
7
      
-
      
1,683
  
Total investments   $
21,899
     $
116
     $
40
     $
(1
 )   $
22,054
  
Schedule of Receivables from Collaborations [Table Text Block]
    March 31, 2020
    Billed   Unbilled   Total
U.S. Department of Health and Human Services   $
-
     $
2,343
     $
2,343
  
Shionogi & Co. Ltd.    
1,679
      
3
      
1,682
  
Green Cross Corporation    
1,186
      
8
      
1,194
  
Mundipharma International Holdings Limited    
18
      
-
      
18
  
Seqirus UK Limited    
405
      
-
      
405
  
Total receivables   $
3,288
     $
2,354
     $
5,642
  
    December 31, 2019
    Billed   Unbilled   Total
U.S. Department of Health and Human Services   $
1,353
     $
15,023
     $
16,376
  
Shionogi & Co. Ltd.    
1,336
      
4
      
1,340
  
Green Cross Corporation    
2,924
      
8
      
2,932
  
Mundipharma International Holdings Limited    
56
      
-
      
56
  
Seqirus UK Limited    
1,091
      
351
      
1,442
  
Total receivables   $
6,760
     $
15,386
     $
22,146
  
Disaggregation of Revenue [Table Text Block]
    2020   2019
Product sales   $
218
     $
1,679
  
Royalty revenues    
1,945
      
2,322
  
Collaborative and other research and development revenues:                
U.S. Department of Health and Human Services    
1,607
      
1,886
  
Torii Pharmaceutical Co., Ltd.    
1,053
      
-
  
Total collaborative and other research and development revenues    
2,660
      
1,886
  
                 
Total revenues   $
4,823
     $
5,887